VFP-011 | VFP-013 | VFP-015

Selected from more than hundred hit molecules a new family of prodrugs has been designed. The core skeleton of these molecules as well as their key chemical features prefigure an acetylcholinesterase (AChE) inhibitor like donepezil (AriceptTM) or rivastigmine (ExelonTM) but one of these features has been chemically hidden in order to mask the biological activity towards the targeted enzyme: such a prodrug is expected to minimize the deleterious peripheral side-effects generally observed with the current symptomatic treatment of AD.

The development strategy of Alzex has been based on a strong intellectual property covering preliminary research on AD drugs and leading to a first general patent (WO2006/103120). This patent has been granted in Europa, North America, Israel... at the end of the 2010s via the international procedure PCT.

This mother patent has been originally filed by the French partner and repurchased by Alzex in 2022. Right now, the data in possession of Alzex gathered all the scientific results of the mother patent and the future selection one as well as all the further developments leading to the final lead compounds.
These data include the full chemical developments (synthesis and analysis) and the biological trials (in house or CROs).

Alzex I.P. is unique in the synthesis and complete analysis of newly discovered compounds and ongoing research is actually scaling-up Standard Operating Procedures (S.O.P.) to a reliable high-scale production of the best compounds in order to get ready for Good Manufacturing Production (GOP) in subsequent planned trials. These steps are essential in a Regulatory Functional Planning of these newly discovered molecules.